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Cardiac-specific Conditional 
Knockout of the 18-kDa 
Mitochondrial Translocator Protein 
Protects from Pressure Overload 
Induced Heart Failure
Phung N. Thai1, Daniel J. Daugherty2, Bert J. Frederich1, Xiyuan Lu3, Wenbin Deng2, 
Donald M. Bers  3, Elena N. Dedkova 3 & Saul Schaefer  1,4
Heart failure (HF) is characterized by abnormal mitochondrial calcium (Ca2+) handling, energy failure 
and impaired mitophagy resulting in contractile dysfunction and myocyte death. We have previously 
shown that the 18-kDa mitochondrial translocator protein of the outer mitochondrial membrane 
(TSPO) can modulate mitochondrial Ca2+ uptake. Experiments were designed to test the role of the 
TSPO in a murine pressure-overload model of HF induced by transverse aortic constriction (TAC). 
Conditional, cardiac-specific TSPO knockout (KO) mice were generated using the Cre-loxP system. 
TSPO-KO and wild-type (WT) mice underwent TAC for 8 weeks. TAC-induced HF significantly increased 
TSPO expression in WT mice, associated with a marked reduction in systolic function, mitochondrial 
Ca2+ uptake, complex I activity and energetics. In contrast, TSPO-KO mice undergoing TAC had 
preserved ejection fraction, and exhibited fewer clinical signs of HF and fibrosis. Mitochondrial Ca2+ 
uptake and energetics were restored in TSPO KO mice, associated with decreased ROS, improved 
complex I activity and preserved mitophagy. Thus, HF increases TSPO expression, while preventing this 
increase limits the progression of HF, preserves ATP production and decreases oxidative stress, thereby 
preventing metabolic failure. These findings suggest that pharmacological interventions directed at 
TSPO may provide novel therapeutics to prevent or treat HF.
Congestive heart failure (HF) is still one of the leading causes of death, despite advances in therapeutic options1. 
Current therapies aim at treating the systemic neurohormonal changes that occur during HF2, but none have 
been successfully developed to directly address cardiomyocyte function and viability. Understanding some of 
the key myocyte abnormalities in HF and developing specific therapies toward reversing these abnormalities 
can improve cardiac function and survival. Several abnormalities related to mitochondrial function have been 
observed in HF, including impairment of intracellular calcium (Ca2+) homeostasis3,4, reduced cellular respira-
tion5,6, increase in the production of reactive oxygen species (ROS), and impaired mitochondrial quality control 
(mitophagy)7, all contributing to reduced contractile function8 and reduced myocyte survival9. These events all 
involve, in part, the proper communication between Ca2+ and mitochondria10.
During excitation-contraction coupling, the influx of Ca2+ through the voltage-gated Ca2+ channels trig-
gers Ca2+-induced Ca2+ release from the ryanodine receptors (RyR2) on the sarcoplasmic reticulum (SR). Areas 
with high, localized concentrations of Ca2+, known as microdomains, form at the junction between the SR and 
mitochondria, and result in mitochondrial Ca2+ uptake11,12. In the normal heart, Ca2+ enters the mitochon-
dria through the voltage-dependent anion channel (VDAC) on the outer mitochondrial membrane (OMM)13 
before it passes through the mitochondrial Ca2+ uniporter (MCU) in the inner membrane14. It is known that 
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mitochondrial Ca2+ serves as a regulator of energy production6,14,15. However, during HF, mitochondrial Ca2+ 
uptake is typically reduced3,14,16, which can impact the production of energy and contribute to the pathogenesis 
of HF.
The 18-kDa translocator protein (TSPO) is a five transmembrane domain protein that is primarily localized in 
the OMM and ubiquitously expressed throughout the body with elevated expression in steroid-synthesizing tis-
sues, such as adrenal glands, gonads and the brain, as well as in the heart17. In addition to regulating steroidogen-
esis18, there is evidence that TSPO is involved in modulating oxidative stress19, and, critically, mitochondrial 
physiology and metabolism20. These latter effects include modulation of Ca2+ transport21, regulation of transcrip-
tion of genes involved in mitochondrial electron transport chain, and thus ATP production22, and mitochondrial 
quality control23.
The above effects of TSPO could be explained via modulation of VDAC23, a ubiquitous channel located on the 
OMM which regulates the energy balance of mitochondria, serving as a common pathway for metabolite exchange 
between mitochondria and the cytoplasm24. Alterations in VDAC function, expressed as open-probability (Po), 
can impact oxidative phosphorylation by controlling the rate of adenine nucleotide exchange across the OMM25. 
Recent evidence has shown that expression of the TSPO is increased during stress conditions26–30, with the degree 
of expression reflecting the severity of the condition31. Thus, conditions which increase TSPO expression, such 
as HF, can modulate metabolism and affect cell survival through its effect on VDAC Po; however, no data exist on 
the role played by TSPO during HF development. Our previous work showed that altering TSPO activity with a 
pharmacologic ligand protoporphyrin IX (hemin) decreased Ca2+ uptake in mitochondria isolated from cardiac 
tissue by decreasing the open probability of VDAC21, which raises the possibility that TSPO may play a role in 
mitochondrial Ca2+ handling.
The objectives of the present study were to test the hypotheses that: a) HF increases expression of TSPO, with 
a concomitant decrease in inward mitochondrial Ca2+ entry and systolic function; and thus b) genetic modula-
tion of the TSPO could normalize mitochondrial Ca2+ uptake and prevent the abnormalities in cardiac structure 
and function evident in HF, specifically by normalizing cellular energetics and redox balance inside cardiomy-
ocytes. These hypotheses were tested using a cardiomyocyte-specific, conditional knockout of the TSPO in a 
murine model of pressure-overload HF. Our studies show for the first time that TSPO-KO animals were protected 
from the progression of HF when compared to wild-type (WT) controls. In concordance with this protection, 
TSPO-KO mice had elevated activity of the mitochondrial complex I which led to the reduction of the oxidative 
stress in TSPO-KO TAC mice, shifting redox balance toward a more reduced state and preserving the mito-
chondrial membrane potential (ΔΨm). Accordingly, the TAC-induced decline in mitochondrial Ca2+ uptake was 
prevented in TSPO-KO vs. WT mice, with correspondent preservation of ATP generation. Furthermore, the 
signaling cascade activating the removal of damaged mitochondria via mitophagy was significantly impaired 
in WT TAC and restored in TSPO KO cardiomyocytes, thus contributing to improved mitochondrial function. 
Together, these data suggest that TSPO can be a potential pharmacological target to correct the abnormalities in 
mitochondrial Ca2+ transport and mitochondrial bioenergetics associated with HF.
Results
TSPO expression is upregulated in pressure overload-induced heart failure. To examine the role 
of the TSPO, we generated cardiac-specific, conditional TSPO-KO mice using the Cre-loxP system as described 
in Methods and illustrated in Fig. 1A 32. DNA was taken from tails, amplified using polymerase chain reaction, 
processed through DNA electrophoresis, and visualized under UV lighting (Fig. 1B). WT animals showed bands 
at 935 base pairs (bp), while KO animals displayed bands at 201 bp confirming that the homozygous line for Tspo 
containing loxP sites was established.
To determine if the TSPO has a role in HF, we induced pressure-overload by surgical transverse aortic con-
striction (TAC) in 11-12 week-old mice. Representative images in Fig. 1C depict an aorta from a sham mouse 
(left) and an aorta from a mouse after one week of TAC (right). The degree of constriction was verified by color 
and pulse wave measurements of flow velocity in both carotid arteries one week after surgery (Fig. 1D,E), with 
values of 6.3 ± 0.4 mm/sec and 6.2 ± 0.4 mm/sec in wild-type TAC (WT TAC) and TSPO knockout TAC (KO 
TAC) mice, respectively (Fig. 1E). These measurements demonstrated identical increases in flow velocity follow-
ing a week of TAC, indicating similar degrees of aortic constriction in the WT and KO animals. After 8 weeks, 
hearts were harvested and mitochondria were isolated from the whole hearts. As seen in Fig. 1F,G, 8 weeks of 
pressure-overload increased TSPO protein expression in the mitochondrial fraction of hearts from WT animals 
by 164% (p < 0.01, n = 4 hearts) over sham controls (WT sham, n = 4 hearts), an increase that was abrogated in 
the KO animals. As demonstrated by immunohistochemistry (Supplementary Fig. 1), very low TSPO levels are 
likely due mainly to TSPO in cells types other than cardiac myocytes where TSPO upregulation by inflammation 
has been reported previously33,34. These results provide the first evidence that cardiac TSPO is upregulated in 
failing hearts following TAC.
TSPO ablation slows progression toward heart failure following TAC surgery. To determine if 
TSPO has an adaptive or maladaptive effect on the development of pressure-overload HF, the anatomic and phys-
iologic responses to pressure-overload were assessed weekly by echocardiography monitoring in unconscious 
mice. Sham animals, both WT and KO, did not exhibit morphologic or performance changes in the 8-week 
observation period after sham surgery. After TAC surgery, the increases in wall thickness after one week were 
similar in the WT and KO animals (Fig. 2A), which further supports a similar hemodynamic load in the two 
TAC groups. Following the initial hypertrophic compensation to the increase in afterload with TAC, the pro-
gression toward cardiac dilatation was significantly slower in KO TAC than WT TAC as manifest in both left 
ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic dimension (LVESD) (Fig. 2B,C). 
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Similarly, WT TAC mice had more cardiac dilation than KO TAC mice, illustrated in the short axis m-mode 
images (Fig. 2D) and significantly higher ventricular cavity area (Fig. 2E, p < 0.01). These changes demonstrate 
the development of a dilated cardiomyopathy in the WT TAC animals, with relative preservation of chamber size 
in the KO TAC animals.
In parallel with the differences in wall thickness and ventricular dimensions, WT TAC animals developed 
reduced systolic function. As seen in Fig. 2F, WT animals subjected to TAC had a significant reduction in ejection 
fraction (EF) from 63.9 ± 1.0% at baseline to 34.5 ± 2.4% after 8 weeks (p < 0.01). In contrast, EF was minimally 
reduced in the KO TAC animals, from 65.5 ± 1.5% at baseline to 55.8 ± 2.0% after 8 weeks of TAC, resulting in 
a significant difference in final ejection fraction between the groups (p < 0.001, Fig. 2F, Table 1). Representative 
images of m-mode echocardiography demonstrate these changes in ventricular dimensions and ejection fraction 
(Fig. 2G). Together, these in vivo data indicate that knocking out TSPO limited HF development and preserved 
cardiac function with pressure overload.
TSPO deletion protects the heart against pressure overload-induced hypertrophy and patho-
logical cardiac remodeling. To further characterize the severity of HF development, anatomical and 
histological analyses were conducted. Consistent with the echocardiographic findings, measurement of heart 
weight-to-tibial length (HW:TL) ratios revealed greater TAC-induced cardiac mass (due to greater dilation) 
in WT compared to KO animals (16.4 ± 1.0 vs 14.0 ± 1.2 mg/mm, p < 0.05, n = 14–18 hearts, Fig. 3A,B). 
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Figure 1. Transverse aortic constriction (TAC) significantly increased TSPO expression in WT mice, which 
was limited in the KO model. (A) A diagram of the Cre-LoxP system used to knockout the TSPO. Tamoxifen 
injection activated Cre recombinase, which excised exons 2 and 3 (arrowheads), thereby rendering the TSPO 
gene inactive. (B) A representative image of an agarose gel under UV lighting confirmed the loxP inserts 
flanking the TSPO, with WT displaying a band at 935 base pairs, and KO having a band at 201 base pairs. (C) 
Both WT mice and KO mice underwent transverse aortic constriction to induce heart failure. Representative 
images show a normal aorta, and an aorta that has been banded. AA = ascending aorta, TA = transverse aorta, 
DA = descending aorta. (D) After a week of TAC, Doppler flow velocity was taken in mice at the right common 
carotid (RCC) and left common carotid (LCC) to ensure the same degree of constriction. Representative images 
show tracings of flow velocity of the left and right common carotids in a WT TAC mouse. (E) The ratio of the 
RCC and LCC show similar degree of banding after TAC. (F) Representative western blot image for TSPO 
and COXIV (the loading control) in the 4 experimental groups [from the same gel] (G) revealed a significant 
increase in the TSPO expression level (normalized to COX IV) with TAC in the WT animals compared to 
sham controls and to KO TAC (n = 4 for all groups). Data expressed as mean ± SEM. ‡p < 0.01 vs WT sham, 
**p < 0.01 vs corresponding sham group, ##p < 0.01 vs WT TAC.
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Abnormalities in histology paralleled the gross anatomic changes, including higher collagen formation in WT 
TAC mice than KO TAC mice (9.2 ± 0.8% and 3.9 ± 0.4%, respectively; n = 3–4 hearts p < 0.01, Fig. 3C,D). These 
data show that KO TAC animals were relatively protected from TAC-induced cardiac remodeling.
In addition to the anatomical, functional, and structural changes, WT TAC mice had more clinical evidence 
of pulmonary congestion confirmed by a higher lung weight-to-tibial length (LW:TL) ratio (13.8 ± 1.9 mg/mm, 
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Figure 2. TSPO-KO TAC mice showed slower progression toward heart failure. (A) WT TAC mice and KO 
TAC mice had similar increases in wall thickness after 1 week, which was significantly different at 8 weeks. (B) 
Left ventricular end diastolic diameter (LVEDD) and (C) left ventricular end systolic diameter (LVESD) showed 
progressive cardiac dilation in WT TAC mice. (D) Representative images show m-mode short axis pictures of 
the heart in all four groups. (E) Endocardial area showed significantly higher cardiac dilation in WT TAC mice 
compared to KO TAC mice. (F) Systolic function, as measured by ejection fraction, showed that WT TAC mice 
had worse cardiac function starting at week 2. (G) Representative m-mode parasternal short axis images for all 
four groups after 8 weeks of sham or TAC surgery show that systolic dysfunction is most evident in WT TAC 
mice. n = 14, 9, 22, and 23 for WT sham, KO sham, WT TAC, and KO TAC respectively in (A–C and F). Data 
expressed as mean ± SEM. *p < 0.05 for WT TAC vs KO TAC, **p < 0.01 for WT TAC vs KO TAC.
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n = 18) than their corresponding sham group (8.2 ± 0.2 mg/mm, n = 5, p < 0.01, Fig. 3E). In contrast, KO TAC 
mice did not experience a significant increase in the LW:TL ratio compared to sham controls. WT TAC mice 
exhibited significantly lower body weight (28.5 ± 0.7 g) compared to sham controls (31.0 ± 0.3 g, p < 0.01), while 
KO TAC mice did not (31.8 ± 0.8 g, Fig. 3F). Consistent with clinical signs of HF, there was a significant increase 
in atrial natriuretic peptide hormone (ANP) mRNA levels in both TAC groups when compared with their cor-
responding sham controls (Fig. 3G), although the WT TAC mice experienced a greater increase in ANP than 
did the KO TAC mice (p < 0.05). Furthermore, the size of cardiac myocytes, determined by confocal fluorescent 
microscopy imaging, was significantly increased in WT TAC (n = 80, P < 0.001) animals compared to WT shams 
(n = 56) (Fig. 3H). Cardiomyocyte cell size was also significantly smaller in KO TAC (p < 0.005, n = 66) compared 
to WT TAC, indicating that TSPO-KO also limited pathological myocyte hypertrophy. Taken together, TSPO KO 
mice develop compensated hypertrophy in response to TAC, whereas WT mice progress fully to HF in the same 
8 week period (based on EF, chamber size, cardiac fibrosis, lung weight and ANP expression).
Cardiac TSPO-KO prevented TAC-induced impairment of mitochondrial Ca2+ uptake. HF has 
been characterized by an alteration in mitochondrial Ca2+ uptake14,16. Our previous work using hemin-induced 
TSPO activation suggested that TSPO can suppress mitochondrial Ca2+ uptake21. The current study used the WT 
vs. TSPO-KO to test whether the dramatic rise in TSPO in TAC might contribute to reduced mitochondrial Ca2+ 
in TAC. Mitochondrial Ca2+ uptake amplitude (assessed using X-Rhod-1), was similar in myocytes from WT 
and TSPO-KO mice under sham conditions (Fig. 4A–C). However, TAC caused a dramatic 86–93% reduction in 
WT mouse mitochondrial Ca2+ uptake at the three [Ca2+] studied (Fig. 4B,C). In sharp contrast, TSPO-KO mice 
exhibited nearly unaltered mitochondrial Ca2+ uptake after TAC (<20% reduction at 1.35 µM Ca2+, no change at 
2 µM Ca2+ and slight increase at 10 µM Ca2+). Moreover, after TAC, mitochondrial Ca2+ uptake in KO myocytes 
was 7.7–9.5-fold higher than that in WT (black vs. green bars in Fig. 4C). We conclude that normal physiologi-
cal levels of TSPO expression do not limit acute mitochondrial Ca2+ uptake, but that the high levels of TSPO in 
TAC-WT may contribute to reduced mitochondrial Ca2+ uptake. Thus, preventing the TAC-induced increase in 
TSPO expression in HF by conditional cardio-specific silencing of TSPO preserved mitochondrial Ca2+ uptake.
Since opening of the mitochondrial permeability transition pore (mPTP) has been associated with Ca2+ 
overload35, increased ROS36 and resultant myocyte death, the effect of TSPO-KO on mPTP was examined using 
calcein release from mitochondria37–39. Figure 4D shows that both WT and TSPO-KO sham had a similar low 
mPTP activity that increased progressively (and similarly) as [Ca2+] was raised. Myocytes from TAC hearts (both 
WT and TSPO-KO) exhibited higher mPTP opening at any given [Ca2+], but no differences in mPTP activity 
were seen between TSPO-KO and WT TAC myocytes (Fig. 4D). These data indicate that TAC caused increased 
mPTP activation, but TSPO ablation did not prevent this effect. Of note, the high mPTP rate in WT TAC mito-
chondria occurred at a lower free mitochondrial [Ca2+] (Fig. 4C), so this might reflect a higher ROS level in the 
HF myocytes that would promote mPTP at lower free [Ca2+]. We also measured basal levels of total mitochon-
drial Ca2+ content measured in isolated mitochondria lysed in 0Ca2+/0Na+ conditions. Baseline total mitochon-
drial Ca2+ was elevated in both WT TAC and KO TAC compared to their corresponding sham controls (Fig. 4E); 
as higher total mitochondrial Ca2+ content also promotes mPTP40, this might explain the similar mPTP in WT 
TAC vs. KO TAC mitochondria.
ATP generation was reduced in WT TAC mice, but preserved in TSPO-KO TAC mice. Ca2+ entry 
into the mitochondria can regulate energy production via activation of several key dehydrogenases3,14,16, and 
enhancing mitochondrial Ca2+ in the context of HF can maintain NADH oxidation3 and, hence ATP production6. 
To assess substrate-dependent [ATP] changes in intact cells under substrate conditions which activate complex I 
(pyruvate/glutamate - Fig. 5A,B) or complex II (succinate - Fig. 5C,D), we monitored changes in [ATP]i indirectly 
using [Mg2+]-sensitive dye mag-fluo-4 (free [Mg2+]i rises as [Mg-ATP] declines)37. Substrate addition led to an 
increase in ATP level above baseline in all groups, which was significantly higher in KO sham cardiomyocytes 
WT KO p-values
Sham 
(n = 14)
TAC 
(n = 22)
Sham 
(n = 9)
TAC 
(n = 23)
WT sham vs 
WT TAC
KO sham vs 
KO TAC
WT TAC vs 
KO TAC
Echocardiography Measures
Heart Rate (bpm) 493 ± 41 523 ± 44 507 ± 41 517 ± 50 NS NS NS
Ejection Fraction (%) 62.7 ± 2.5 34.5 ± 2.4 63.4 ± 2.8 55.8 ± 2.0 <0.01 <0.05 <0.05
LVEDD (mm) 3.89 ± 0.08 4.79 ± 0.10 3.91 ± 0.04 4.16 ± 0.06 <0.01 <0.01 <0.01
LVESD (mm) 2.53 ± 0.13 3.98 ± 0.15 2.56 ± 0.15 2.95 ± 0.10 <0.01 <0.05 <0.05
LVAW,d (mm) 0.71 ± 0.02 0.96 ± 0.02 0.73 ± 0.01 1.07 ± 0.03 <0.01 <0.01 <0.01
LVAW,s (mm) 1.09 ± 0.03 1.21 ± 0.03 1.14 ± 0.02 1.47 ± 0.04 <0.01 <0.01 <0.01
LVPW,d (mm) 0.72 ± 0.02 0.95 ± 0.01 0.74 ± 0.02 1.06 ± 0.03 <0.01 <0.01 <0.01
LVPW,s (mm) 1.10 ± 0.03 1.21 ± 0.03 1.15 ± 0.03 1.47 ± 0.04 <0.01 <0.01 <0.01
Table 1. Echocardiographic parameters of WT and KO mice at 8 weeks after sham or TAC surgery. 
Abbreviations: LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; 
LVAWd, left ventricular anterior wall during diastole; LVAWs, left ventricular anterior wall during systole; 
LVPWd, left ventricular posterior wall during diastole; LVPWs, left ventricular posterior wall during systole. 
Data expressed as mean ± SEM.
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Figure 3. WT TAC mice developed worse dilated cardiomyopathy, and showed greater clinical manifestations 
of heart failure. (A) Representative heart pictures of all four groups show enlargement of hearts in TAC animals, 
with worse phenotype in the WT TAC heart including left atrial enlargement. (B) Postmortem analysis of heart 
weight-to-tibial length ratio indicated greater heart weight in WT TAC mice compared to hearts of either sham 
group or the KO TAC mice. (C) Representative photographs of transverse sections showed greater fibrosis in the 
hearts of WT TAC mice, which quantitatively had a (D) collagen volume fraction that was significantly higher 
than the fraction in KO TAC hearts; n = 4 hearts for all groups. (E) Postmortem lung weight-to-tibial length 
measurements showed evidence of pulmonary effusion in WT TAC mice. (F) WT TAC mice lost significantly 
more weight, while KO TAC mice gained weight, consistent with more severe HF in WT TAC. (G) Relative 
mRNA expression of ANP showed a much greater increase in atrial natriuretic peptide (ANP), a typical 
biomarker of heart failure, in WT TAC mice. (H) Cell size was significantly increased WT TAC cardiomycytes 
compared to WT and KO shams, and TSPO-KO TAC. n = 3–4 hearts. Data expressed as mean ± SEM. 
**p < 0.01 vs corresponding sham group, #p < 0.05 vs WT TAC, ##p < 0.01 vs WT TAC.
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compared to WT sham cardiomyocytes in the presence of pyruvate/glutamate (p < 0.01), but not in the presence 
of methyl-succinate. This finding suggests that complex I mediated respiration drove significantly more ATP 
production in KO sham cardiomyocytes vs. WT. With methyl-succinate to drive complex II mediated respiration, 
there was no difference between WT and KO shams (Fig. 5C,D). In WT mouse myocytes, TAC nearly abolished 
the ATP rise induced by either pyruvate and glutamate or methyl-succinate. However, in TSPO-KO TAC myo-
cytes, ATP levels achieved were higher than in the WT animals after TAC for either substrate (albeit still lower 
than sham).
Corresponding to the improved ATP levels in the TSPO-KO TAC animals (vs. WT TAC), TSPO ablation 
resulted in restoration of the mitochondrial reserve capacity in TSPO-KO TAC cardiomyocytes utilizing substrate 
for either mitochondrial complex I or II (Fig. 5B,D, right panels). Furthermore, the reserve capacity was higher in 
sham TSPO-KO vs. WT mice, but only for pyruvate/glutamate as substrates for mitochondrial complex I.
Together, these data confirm the adverse effect of TAC-induced heart failure on ATP production37,41 and sug-
gest that the effects of the TSPO-KO cardioprotection after TAC may be mediated by enhancement of energy 
production via complex I.
Mitochondrial FAD redox potential remained more reduced in TSPO-KO TAC animals. It has 
been previously reported that restoring mitochondrial Ca2+ uptake in the failing hearts plays an essential role 
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in maintaining the NADH/FAD redox balance3. We therefore hypothesized that the inability of cells to maintain 
normal mitochondrial Ca2+ uptake in WT TAC mice could contribute to dysregulation of the redox potential 
and electron flux. To test that hypothesis, we monitored mitochondrial redox potential by FAD/FADH2 autoflu-
orescence under conditions of increased cell work induced by electrical field stimulation at 4 Hz and subsequent 
isoproterenol (ISO) stimulation (Fig. 6A).
Quantitative analysis in WT TAC cardiomyocytes revealed nearly maximal FAD/FADH2 ratio (oxidized) at 
basal conditions, significantly more oxidized than WT sham (0.94 ± 0.01, n = 10 vs 0.56 ± 0.04, n = 14, p < 0.001, 
Fig. 6B). Most importantly, we found WT TAC myocytes were not able to maintain a redox state when cells were 
exposed to high work load induced by 4 Hz stimulation (FS) with isoproterenol. That is, the degree of FAD reduc-
tion, which inversely correlates with NADH oxidation, was nearly ten-fold higher in WT TAC cardiomyocytes vs. 
WT sham cardiomyocytes (Fig. 6C). In TSPO-KO TAC cardiomyocytes, there was still significant reduction in 
FAD/FADH2 with stimulation plus isoproterenol, but this was significantly smaller when compared to WT TAC 
myocytes (−0.16 ± 0.1, n = 10 vs −0.29 ± 0.2, n = 10, p < 0.001). In both WT and KO sham cardiomyocytes, 
FAD/FADH2 levels were well maintained during 4 Hz FS and ISO stimulation (Fig. 6C). These data suggest a 
possible impairment in the electron flow at the level of the respiratory chain in WT TAC mice which was partially 
restored in KO TAC mice.
Complex I activity was impaired in WT TAC and associated with decreased mitochondrial mem-
brane potential and enhanced ROS generation. We41 and others42 previously reported that electron 
transfer during HF is impaired at the level of the mitochondrial complex I, which can increase ROS accumu-
lation. We found that WT TAC mice had reduced complex I activity compared to WT sham mice (7.4 ± 0.3 vs 
8.5 ± 0.2 mOD/min, p < 0.01), whereas KO TAC mice had preservation of complex I activity (similar to KO 
sham). Importantly, we found that complex I activity after TAC was much higher in TSPO-KO vs. WT mice 
(9.5 ± 0.3 vs 7.4 ± 0.3 mOD/min, p < 0.01, Fig. 6D). Together, these data show that complex I activity is impaired 
in WT TAC mice, but preserved in KO TAC mice.
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To examine whether KO TAC mice have less ROS generation compared to WT TAC mice, superoxide gener-
ation was measured in cardiomyocytes using MitoSOX Red fluorescent dye38,39. Figure 6E shows that WT cardi-
omyocytes had significantly higher superoxide production both under sham conditions and after TAC, following 
electrical field stimulation at 0.5 Hz or beta-adrenergic stimulation with 100 nM isoproterenol. Notably, superox-
ide generation in cardiomyocytes from KO TAC animals was similar to that of sham animals (1.02 ± 0.01, n = 10 
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vs 1.04 ± 0.01, n = 19, p = 0.1). Together, these data show that ROS generation was increased by HF in WT TAC 
mice, and limited to control levels in TSPO-KO animals.
Furthermore, we found that mitochondrial membrane potential (ΔΨm) was significantly decreased in WT 
TAC cardiomyocytes, but not in TSPO-KO TAC (Fig. 6F). Application of 10 µM rotenone, a mitochondrial com-
plex I inhibitor, led to a significant decrease in ΔΨm in WT sham from 1516 ± 89 to 858 ± 43 a.u., n = 39, p < 0.001 
but not in WT TAC myocytes where basal level was already at 911 ± 24 a.u., n = 17 (not shown), confirming that 
the inability of mitochondria to maintain ΔΨm in HF was related to impairment of the mitochondrial complex I. 
In TSPO-KO TAC mice, basal levels of ΔΨm were significantly closer (1404 ± 72 a.u., n = 24) to that observed in 
sham controls (1567 ± 81 a.u., n = 39). We conclude that TSPO ablation improved mitochondrial oxidative phos-
phorylation via restoration of the electron flux flow at the level of the mitochondrial complex I.
Mitophagy was impaired in WT TAC, but preserved in KO TAC cardiomyocytes. Efficient degra-
dation and replacement of dysfunctional mitochondria is essential for cardiac myocyte survival. Damaged mito-
chondria are eliminated via mitochondrial autophagy or mitophagy. Upon mitochondrial depolarization, the 
serine/threonine kinase PTEN-inducible kinase 1 (PINK1) accumulates on the mitochondrial surface, recruiting 
the E3 ubiquitin ligase (Parkin) to the outer mitochondrial membrane from the cytosol. Parkin then polyubiq-
uitinates mitochondrial membrane proteins, marking them for degradation and recognition by the adaptor pro-
tein SQSTM1/p62. SQSTM1/p62 binds to the microtubule-associated protein 1A/1B-light chain 3 (LC3) on the 
autophagosome and to the ubiquitinated mitochondrial proteins, tethering the autophagosome to the mitochon-
drion7. The autophagosome then engulfs the mitochondrion and fuses with lysosomes, allowing mitochondrial 
proteins to be degraded and recycled.
We evaluated mitophagy by monitoring mitochondrial Parkin accumulation and LC3-mediated autopha-
gosome formation in cardiac myocytes using confocal microscopy. As shown in Fig. 7A–C, WT TAC myocytes 
exhibited increased mCherry-Parkin puncta accumulation (marking damaged mitochondria) which was not 
accompanied by an increase in LC3-mediated autophagosome formation. This indicates impairment of mito-
phagy flux in TAC-induced HF. In contrast, mitophagy flux was enhanced in TSPO KO TAC mice (i.e. lower 
accumulation of Parkin puncta, but more LC3-autophagosomes). While lower levels of both mCherry-Parkin 
and LC3-GFP puncta were observed in WT sham myocytes, both were increased in TSPO KO sham myocytes, 
consistent with potential TSPO-induced suppression of mitophagy even in control myocytes. These results were 
further confirmed by blots assessing key proteins involved in mitophagic signaling. There were no significant 
changes in PINK-1 expression among the groups (Fig. 7D,E); however, WT TAC had reduced expression of 
TOMM22, which imports PINK1 into the mitochondrial matrix for cleavage by mitochondrial processing pro-
teinase (MPP) and presenilin-associated rhomboid-like (PARL; Fig. 7D,G). Conversely, expression of the adaptor 
protein SQSTM1/p62 was greatest in WT TAC, but this did not correlate with LC3-II levels (Fig. 7D,G). In TSPO 
KO TAC myocytes, TOMM22 levels were partially increased while p62 levels were lower compared to WT TAC 
samples; however, the conversion of LC3-I to LC3-II was improved (Fig. 7D–G). As LC3-II is a lipidated form 
of LC3-I that localizes on phagophores and autophagosomes, the LC3-II/LC3-I ratio is indicative of mitophagic 
flux and was highest in KO TAC myocytes. Taken together, these measurements demonstrate that there was an 
increase in the removal of damaged mitochondria via mitophagy in KO TAC cardiomyocytes, but that this mito-
phagic flux was impaired in WT TAC cardiomyocytes.
Discussion
Our results yield several key findings with respect TSPO function in pressure-overload induced heart failure 
(TAC). First, we demonstrated that TAC resulted in a 3-fold increase in expression of the TSPO in WT animals 
(Fig. 1F,G), an upregulation of TSPO that parallels that seen in cardiac ischemia and reperfusion29 and under 
stress conditions in other tissues27,28,30. Pressure overload for 8 weeks in WT animals resulted in the expected 
changes in cardiac morphology, function, and metabolism associated with HF (see Figs 2 and 3, and Table 1). 
These included an increase in cardiac chamber size, a 46% decrease in ejection fraction, an increase in myocyte 
hypertrophy and fibrosis, and clinical signs of HF such as pulmonary congestion and an increase in atrial natriu-
retic peptide.
Second, this study demonstrated that cardiac-specific conditional KO of TSPO substantially abrogated the del-
eterious effects of TAC. By preventing TSPO upregulation during TAC, there was well-preserved left ventricular 
function (only 15 vs. 46% reduction in ejection fraction in TSPO-KO vs. WT animals). In addition, TSPO-KO 
decreased associated HF markers, with lower levels of ventricular dilation, pulmonary congestion, ANP levels and 
extents of cardiac fibrosis and hypertrophy.
Third, TSPO-KO had several salutary effects on mitochondrial function in TAC mice, including normaliza-
tion of mitochondrial Ca2+ uptake (Fig. 4) and ATP production (Fig. 5), lower production of ROS, maintenance 
of mitochondrial membrane potential, redox state (Fig. 6) and preservation of mitophagy (Fig. 7). Remarkably, 
the TSPO-KO at baseline (sham) was not appreciably different than the WT sham in any of the parameters that 
we assessed. We conclude from this observation that physiological levels of TSPO expression do not have overt 
negative effects, but that the dramatic upregulation of TSPO in TAC (and other stress conditions) has impactful 
negative effects that worsen HF progression and function. It is possible that the TSPO upregulation exceeds the 
stoichiometry of its normal physiological targets or partners, allowing it to interact preferentially with new targets 
that mediate pathological effects.
As a modulator of VDAC43, TSPO can affect inward mitochondrial Ca2+ flux. We have previously shown that 
the TSPO ligand protoporphyrin IX (hemin) reduced Ca2+ uptake in isolated mitochondria21, as was shown with 
another TSPO ligand PK1119544,45. Upregulation of TSPO expression during HF coincided with a decrease in 
mitochondrial Ca2+ uptake, which was normalized in TSPO-KO mice (Fig. 4). Together, these data are consistent 
with excess TSPO being a negative modulator of mitochondrial Ca2+ entry, potentially by interacting with and 
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Figure 7. Impaired mitophagy in WT TAC cardiomyocytes, and preserved mitophagy in KO TAC 
cardiomoycoytes. (A) Representative cardiomyocyte images from all four groups showing cells with mCherry-
Parkin, LC3-GFP, and the combined images of both. (B) Quantitative analysis (puncta count/cell) revealed the 
increase in m-Cherry Parkin in WT TAC cardiomyocytes, but not in KO TAC cardiomyocytes. (C) Further 
quantitative analysis for LC3-GFP (autophagosome formation indication) showed that there was actually a 
decrease in LC3-GFP in WT TAC cardiomyocytes, while LC3-GFP in KO TAC cardiomyocytes increased, 
suggesting that there was increase in mitochondrial autophagy in KO TAC cardiomyocytes and not in WT 
TAC cardiomyocytes. (D) Shown are representative Western blots of the proteins participating in signaling 
cascade that activates mitophagy in cardiac myocytes: PINK-1, SQSTM1/p62, TOMM22, and LC3-I/LC3-II 
in cell lysates from four experimental groups. Actin staining was used to verify equal protein loading for each 
experimental group. (E) Quantification of PINK-1 protein expression normalized to WT sham levels which are 
taken as 100%. (F) Quantification of SQSTM1/p62 protein expression normalized to WT sham levels which are 
taken as 100%. (G) Quantification of TOMM22 protein expression normalized to WT sham levels which are 
taken as 100%. (H) Quantification of SQSTM1/p62 protein expression normalized to WT sham levels which are 
taken as 100%. (I) Quantification of LC3-I protein expression normalized to WT sham levels which are taken as 
100%. (J) Quantification of LC3-I conversion to LC3-II protein expression normalized to WT sham levels which 
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modulating VDAC open probability21. VDAC operates at the OMM, and controls Ca2+ entry into the intermem-
brane space in series with the mitochondrial Ca2+ uniporter (MCU) on the IMM46,47. A recent study13 demon-
strated that reducing Ca2+ flux via VDAC severely affected heart contractility in zebra fish, while interventions to 
increase Ca2+ flux through the OMM restored normal contraction of the heart. These data highlight the possible 
impact of OMM proteins such as VDAC and TSPO in the regulation of mitochondrial Ca2+ uptake and cardiac 
function.
The remarkable beneficial effects of the TSPO-KO (at the mitochondrial, cardiac structure and functional 
level) are consistent with TSPO upregulation being a central amplifier of the progression from compensated 
hypertrophy (seen in TSPO-KO mice after TAC) to more full-blown HF (seen in WT TAC). A primary effect 
of TSPO overexpression to inhibit mitochondrial Ca2+ uptake could lead to most of the mitochondrial sequelae 
(on ATP and ROS production redox state and membrane potential), but we cannot rule out additional primary 
TSPO effects. Better maintenance of mitochondrial and energetic function by TSPO-KO, as seen here during 
TAC, could maintain cardiac function and slow the progression to HF48. Notably, the TSPO-KO TAC mice (vs. 
WT TAC) had higher respiratory reserve values and higher activity of the mitochondrial complex I, indicating 
preservation of mitochondrial bioenergetics. These findings agree with those of Gatliff et al.49 who showed that 
CF35 cells with siRNA-induced TSPO knockdown showed greater mitochondrial ATP production compared 
to control cells, while an overexpression of TSPO decreased ATP. Taken together, our data show that TSPO-KO 
mice were resistant to the progression of HF, and this protective effect was most likely due to a combination of 
enhanced mitochondrial Ca2+ uptake and energy production.
This situation contrasts with the known deleterious effect of mitochondrial Ca2+ overload under acute 
ischemia/reperfusion39,50. With ischemia/reperfusion, significant Ca2+ overload during reperfusion, mediated 
by sarcolemmal Na+/Ca2+ exchanger50,51, can result in opening of the mitochondrial permeability transition 
(mPTP), leading to mitochondrial swelling, membrane rupture and myocyte death. In contrast to the detrimen-
tal effect of Ca2+ overload under this acute pathologic challenge, the better maintained physiological mitochon-
drial Ca2+ uptake during chronic TAC in TSPO-KO promoted improved mitochondrial energetics and cardiac 
function. Notably, mPTP, which is a key turning point in above ischemia/reperfusion damage, was not influenced 
by TSPO-KO (Fig. 4D). Consistent with these findings, cyclosporine A treatment, a known mPTP inhibitor, 
while limiting deterioration of mitochondrial function in HF animals, was not associated with a commensurate 
improvement in cardiomyocyte Ca2+ handling or contractility52.
HF has been shown to result in increased oxidative stress38,53 and a higher FAD/FADH2 ratio54. These abnor-
malities have been shown to result in greater myocyte loss and dysfunction55, observations consistent with those 
observed with progressive HF in the WT TAC animals in the current study. In contrast, TSPO-KO mice demon-
strated preserved function and less fibrosis, coupled with lower oxidative stress. The lower oxidative stress in 
the KO animals is likely due to the preservation of complex I activity38,42, as well as the higher ATP generation 
resulting in activity of key Ca2+-dependent dehydrogenases56.
It is increasingly clear that cardiac mitochondrial ROS production is dynamically regulated by Ca2+, ADP 
and the redox state of mitochondrial pyridine nucleotides57. One aspect is that ROS production can be increased 
by mitochondrial [Ca2+] that is either too high or too low (involving NADH, NADPH and FADH2). This 
“Redox-optimized ROS balance” hypothesis58,59 postulates that the physiological steady state in cardiac mito-
chondria is tuned to an intermediate redox state that prevents excessive ROS formation at the ETC under highly 
reduced conditions60–62, but also maintains anti-oxidative capacity under highly oxidized conditions58,59,63. Our 
data fit with this concept, as basal FAD/FADH2 ratio was 0.56 under sham conditions, with minimal ROS genera-
tion. During HF, however, Ca2+ uptake was depressed and FAD/FADH2 was severely oxidized, with a concordant 
increase in ROS generation. TSPO ablation restored normal Ca2+ flux to mitochondria, improved complex I 
activity, shifting redox index toward an “intermediate state” and reduction in ROS generation (see Fig. 6), which 
ultimately resulted in the improvement of cardiac function in vivo.
Our results are also consistent with results of Gatliff et al.23, in mouse embryonic fibroblasts and canine mam-
mary gland epithelia. They concluded that TSPO, via its interaction with VDAC1, causes mitochondrial uncou-
pling, increased ROS production and inhibition of mitophagy by limiting the Parkin-dependent ubiquination. 
This fits with our data from KO TAC mitochondria, myocytes and hearts, where mitochondrial coupling in com-
plex I was enhanced, ROS levels were lower and mitophagy was preserved vs. WT TAC. Moreover, this enhanced 
mitochondrial health and Ca2+ handling in TSPO KO hearts was associated with dramatically improved cardiac 
functional response to pressure overload, preventing transition from compensated hypertrophy to HF. These 
results should also further stimulate studies aimed at clarifying the detailed molecular mechanisms by which ele-
vated levels of the OMM protein TSPO in HF mediate multiple pathological changes in mitochondrial function 
and turnover.
Limitations
As with any murine animal model, one can neither extrapolate these findings to other HF causes (e.g. myocardial 
infarction, anthracycline toxicity), nor to human or large animal models. TSPO has numerous reported effects on 
steroid transport and lipid metabolism64, porphyrin metabolism65, and fatty acid oxidation66. While beyond our 
present scope, one or more of these pathways could also be involved in the protective effect of TSPO-KO in HF 
besides the mechanisms reported in this study.
are taken as 100%. n = 3–5 animals, 8–15 cells used for each group in confocal microscopy experiments. Data 
expressed as mean ± SEM. *p < 0.05 vs corresponding sham group, **p < 0.01 vs corresponding sham group, 
†p < 0.05 vs WT sham, ‡p < 0.01 vs WT sham, #p < 0.05 vs WT TAC, ##p < 0.01 vs WT TAC.
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Conclusion
Taken together, these experiments have shown that HF induced by pressure overload resulted in increased expres-
sion of TSPO. Abrogating this increase by genetic ablation resulted in cardioprotection reflected by preserved 
ventricular function, cellular histology and clinical signs of heart failure. This cardioprotective effect was associ-
ated with preserved mitochondrial Ca2+ uptake and complex I-mediated respiration leading to the normalization 
of ATP production oxidative stress and mitochondrial quality control. These findings are the first observations 
that modulation of the mitochondrial outer membrane translocator protein could be a target for the prevention 
or treatment of HF.
Methods
All protocols were in accordance with the Guide for the Care and Use of Laboratory Animals published by the 
National Institutes of Health (NIH Publication NO. 85-23, revised 1996) and approved by the University of 
California Davis Institutional Animal Care and Use Committee.
Model of pressure overload hypertrophy/heart failure. C57Bl/6J mice were obtained from The 
Jackson Laboratory (Sacramento, CA). The aorta was surgically constricted as previously described67. A 5-mm 
thoracotomy was made and the transverse aorta was isolated and a suture looped around a blunt 27-gauge needle, 
yielding a transverse aortic diameter of approximately 0.4-mm. The sham procedure was identical except that the 
aorta was not ligated.
Generation of cardiac-specific conditional TSPO−/− mice. TSPO-floxed mice were produced in 
conjunction with the Mouse Biology program at UC Davis. TSPO-floxed mice were bred with mice contain-
ing the Tg(Myh6-cre)1Jmk/J gene (The Jackson Laboratory, Sacramento CA), in order to generate inducible, 
cardiac-specific, conditional KO mice. To genetically determine if TSPO was floxed, DNA was taken from tails, 
amplified using polymerase chain reaction, processed through DNA electrophoresis, and visualized under UV 
lighting. The Tspo gene had normal expression until Cre-mediated deletion of exons 2 and 3, induced by a sin-
gle intraperitoneal injection of 40 mg/kg of tamoxifen (dissolved in sunflower oil and 100% ethanol at a 10:1 
ratio). This recombination created a frame-shift mutation and a premature stop, which rendered the Tspo gene 
inactive. Exons 2 and 3 in the TSPO gene were flanked with loxP sites. This vector construct was inserted into 
C57BL/6 embryonic stem cells, which were subsequently screened through polymerase chain reaction (PCR) and 
DNA electrophoresis. Mice that had loxP sites were bred with each other to form TSPOflox/flox mice. Homologous 
TSPOflox/flox mice were then bred with mice containing the Tg(Myh6-cre)1Jmk/J gene. The Tg(Myh6-cre)1 Jmk/J 
gene controls the expression of Cre recombinase by the mouse myosin, heavy polypeptide 6 (Myh6). Animals that 
were homologous for TSPOflof/flox and had the inducible Cre recombinase were considered to be KOs.
Quantitative Real-Time PCR (RT-PCR). Total RNA was extracted using a RNA fibrous tissue mini kit 
(Qiagen, Hilden Germany) and cDNA synthesized from 1 µg of RNA using the iScriptTM cDNA synthesis kit 
(Bio-Rad, Hercules, CA). qRT-PCR was performed with commercial and customized TaqMan probes (Life 
TechnologiesTM, ThermoFisher Scientific, Grand Island NY. Target gene mRNA level of ANP was normalized to 
GAPDH which served as housekeeping gene for comparison.
Echocardiography. Ventricular function was monitored using 2D echocardiography on a weekly basis using 
a Visualsonics Vevo 2100 echocardiography machine and a MS 550D probe (22–55 MHz). Animals were anes-
thetized using isoflurane (0.75–1%). 2D echocardiography was performed at weekly intervals until the mice were 
ready to be sacrificed after 8 weeks of sham or TAC operation. Ejection fraction was determined from 2D images 
by manual determination of endocardium and epicardium from end-diastolic and end-systolic images.
Morphometric Measurements. Eight weeks after surgery, mice were anaesthetized with isoflurane and 
sacrificed by cervical dislocation. Hearts were excised, weighed and immediately fixed by perfusion in a ret-
rograde manner with 4% paraformaldehyde in phosphate-buffered saline (PBS) followed by immersion fixa-
tion in buffered 4% paraformaldehyde. Hearts were kept at 4 °C before the tissue was processed. Lungs were 
extracted, blotted dry, and weighed. Increased cardiac mass was assessed by comparing the ratios between heart 
weight-to-tibial length. Pulmonary congestion was assessed by comparing lung weight-to-tibial length ratios.
Fibrosis Measurement. Extracted hearts were rinsed with PBS, placed in 10% Neutral Buffered Formalin, 
and paraffin-embedded. Hearts were sliced into 5 µm sections and collagen fibers were stained with Picro-Sirius 
Red stain. Images were taken with an Olympus BH-2 Bright-field Microscope using the 20x objective lens. 
Quantification of fibrosis was performed using ImageJ software.
Cell Isolation. Left ventricular myocytes were isolated using a Langendorff perfusion system38. Briefly, mice 
were anesthetized by inhalation of isofluorane. When the reflexes were absent, hearts were excised, placed into the 
Langendorff system and perfused with a Ca2+-free washing solution, followed by an enzyme solution containing 
Liberase TM (Research Grade, Roche). Freshly isolated ventricular myocytes were stored at room temperature 
and used within 8 hours of isolation.
Mitochondrial Ca2+ Uptake. Myocytes plated on laminin-coated coverslips were loaded with X-Rhod-1 
AM for 40 minutes at 37 °C37,68. Coverslips with the attached cells were placed in a perfusion chamber, and then 
permeabilized with 50 µg/ml Saponin in the intracellular solution containing (in mM): 135 KCl, 0 NaCl, 20 
HEPES, 5 pyruvate, 2 glutamate, 2 malate, 0.5 KH2PO4, 0.5 MgCl2, 15 2,3-butanedione monoxime, 5 EGTA, and 
1.86 CaCl2 to yield a free [Ca2+]i of 100 nM with pH 7.2. After permeabilization, the bath solution was changed to 
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the same intracellular solution but without saponin, and extramitochondrial Ca2+ ([Ca2 +]em) was elevated to ini-
tiate mitochondrial Ca2+ uptake. X-Rhod-1 was excited with the 543-nm line of a green HeNe laser, and emitted 
fluorescence was measured at 552–617 nm. Mitochondrial X-Rhod-1 fluorescence intensity (F) in each experi-
ment was normalized to the level of fluorescence recorded before stimulation (F0) but after cell permeabilization. 
Changes in [Ca2+]m are expressed as ΔF/F0, where ΔF = F − F0.
Basal Mitochondrial Ca2+ Measurement. Mitochondria were isolated from left ventricles using a stand-
ard differential centrifugation method. Briefly, minced hearts were suspended in mitochondrial isolation buffer 
(IB1) in 67 mM sucrose, 50 mM Tris/HCl, 50 mM KCl, 10 mM EDTA, and 0.2% BSA with a pH = 7.2, homoge-
nized with a glass Teflon pestle, and subsequently centrifuged at 700 g for 10 min at 4 °C. The supernatant was 
collected and then spun at 8000 g for 10 min at 4 °C. The pellet was then resuspended in ice-cold buffer (IB2) 
containing 250 mM sucrose, 3 mM EGTA/Tris, and 10 mM Tris/HCl with a pH = 7.2, followed by centrifugation 
at 8000 g for 10 min at 4 °C. Mitochondria were then resuspended in IB2. Protein concentration was measured 
using the Bradford Assay method.
Basal mitochondrial calcium was measured in isolated mitochondria using Molecular Devices Spectra Max 
M5 fluorometer in combination with Ca2+ indicator Rhod-2. A calibration curve was generated in a 96-well 
plate with Ca2+ suspended in deionized water, ranging from 0 µM to 3 µM Ca2+. 10 µg of isolated mitochondria 
were spun down at 8000 g at 4 °C for 10 minutes. The IB2 was then removed from the pelleted mitochondria, and 
replaced with water to lyse the mitochondria. All wells were incubated with Rhod-2 for 30 minutes at 37 °C and 
then measured using a fluorescent plate reader at Ex/Em 552/581 nm.
ATP Measurements. ATP measurements were performed indirectly via the free magnesium (Mg2+) con-
centration using the fluorescent dye mag-fluo-4 (Invitrogen, ThermoFisher Scientific, Grand Island NY)37,68. Since 
free [Mg2+]i is kept constant within a rather narrow range, ATP hydrolysis leads to concomitant increase in free 
[Mg2+]i as measured with fluorescent Mg2+ indicators such as mag-fluo-4. Therefore, an increase in mag-fluo-4 
fluorescence indicates a decrease in ATP concentration. For ATP measurements myocytes were loaded with 
10 µM mag-fluo-4 (λex = 488 nm, λem = 565–605 nm) for 30 min at 37 °C. All data from these measurements are 
expressed as R = 1 − F/F0.
mPTP activity. mPTP activity was monitored in permeabilized myocytes loaded with 5 μM calcein/AM 
(λex = 488 nm, λem = 510 nm) for 40 min at 37 °C37,38. Opening of mPTP resulted in the loss of mitochondria- 
trapped calcein (620 Da) and a decrease of fluorescence. At the end of each recording 10 μg/ml of the pore-forming 
antibiotic alamethicin was applied to provide a control measure for maximum calcein release from mitochondria. 
Loss of mitochondrial calcein induced by elevating Ca2+]em was quantified as the rate of decline of fluorescence 
(d(ΔF)/dt) calculated from the linear fit to the initial decrease of calcein fluorescence. The rate of decline was 
normalized (%) to the basal decline of calcein fluorescence addition (taken as 100%) before [Ca2+]em elevation.
ROS Generation. ROS production was measured in intact myocytes loaded with 0.5 μM MitoSox Red 
(λex = 543 nm, λem = 555–617 nm) for 30 min at 37 °C37,68. Changes in MitoSox Red fluorescence intensity (F) 
were normalized to the level of fluorescence recorded prior to stimulation (F0), and expressed as ΔF/F0.
Mitochondrial Redox State. Flavin adenine dinucleotide (FAD)-linked protein autofluorescence 
(λex = 488 nm, λem = 510 nm) was measured to evaluate mitochondrial redox state37,38,68. Data are presented as 
the ratio of oxidized FAD to reduced FADH2 (FAD/FADH2) calculated as (F − Fmin)/(Fmax − Fmin) where F is the 
fluorescence intensity, and Fmin is the fluorescence obtained after addition of 4 mM NaCN (inhibits respiration 
and promotes maximal FAD reduction, i.e. FADH2 formation), taken as 0%. Fmax is the fluorescence obtained 
after addition of 10 μM FCCP (stimulates maximal respiration, completely oxidizing the mitochondrial FADH2 
pool), taken as 100%.
Mitochondrial Membrane Potential. Changes in mitochondrial membrane potential (ΔΨm) 
were followed using the potential-sensitive dye tetramethylrodamine methyl ester (TMRM; λex = 514 nm, 
λem = 590 nm)37,38,68. Cells were exposed to 5 nM TMRM for 30 min at 37 °C prior to experiments. All solutions 
contained 5 nM TMRM during recordings.
Mitochondrial Complex I activity. We used colorimetric assays (Abcam, Cambridge MA) kits for these 
two complexes. Mitochondria were isolated using the standard procedure stated above. After isolation, proteins 
were extracted from the mitochondria using the provided detergent solution. Twenty micrograms of proteins 
were then loaded into wells pre-coated with antibodies specific for Complex I. Assay time, reagents and buffers 
added, were followed exactly as stated in the protocol booklets for each complex.
Mitophagy measurements. Adenoviral gene transfer in isolated myocytes that were kept in short-term 
culture (24–48 h; multiplicity of infection of 500) was used to express mCherry-Parkin and GFP-LC3 to monitor 
Parkin accumulation in mitochondria and LC3-mediated autophagosome formation69. Freshly isolated myocytes 
were plated on sterile, laminin-coated glass coverslips in PC-1 medium, supplemented with penicillin and strep-
tomycin (50 μg/ml). PINK1, Parkin, SQSTM1/p62, TOMM22 and accumulation of LC3-II were also monitored 
by Western blot.
SDS-PAGE and Western Blotting. Primary antibodies for TSPO (Abcam, ab109497), COX IV (Abcam, 
ab16056), PINK1 (Abcam ab23707), SQSTM1/p62 (Abcam ab56416), TOMM22 (Abcam ab57523), LC3 (MLB, 
M186-3), Parkin (Santa Cruz Biotechnology sc-133167) and β-Actin (Santa Cruz Biotechnology sc-47778) were 
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diluted to a concentration of 1:1000, and secondary antibodies were conjugated with Horseradish Peroxidase was 
diluted to a concentration of 1:2000. Signals were detected using an Alpha FluorChem Imaging Systems 8900 and 
bands were quantified relative to housekeeping protein (Supplementary Fig. 2).
Immunohistochemistry. Hearts were fixed in 4% PFA and then embedded in paraffin. 5 micrometer sec-
tions were cut and these sections were deparaffined in a series of xylene and alcohol concentrations70. Antigen 
retrieval was performed using heat in sodium citrate buffer. Blocking was done at room temperature for 2 hours 
using TBS with 10% goat serum and 1% BSA. Primary antibodies were incubated at 1:300 overnight. TSPO (red, 
ABCAM ab109497) and α-actinin (green, Sigma A7811) were the primary antibodies. Images were taken using a 
Zeiss LSM 700 Confocal Laser Scanning Microscope.
Statistical analysis. All data are expressed as mean ± standard error. Statistical significance of differences 
between experimental groups was determined using Student paired t test or two-way ANOVA, followed by Tukey 
post-test when appropriate. A value of p < 0.05 was considered statistically significant. The datasets generated dur-
ing and/or analyzed during the current study are available from the corresponding author on reasonable request.
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